NIEMANN-PICK DISEASE DRUG TYPE C TREATMENT MARKET ANALYSIS

Niemann-Pick Disease Drug Type C Treatment Market, by Drug Type (Phase III Drug {Trappsol Cyclo, IB1001}, Marketed Drug {Miglustat (Zavesca)}), by Indication (Niemann-Pick Disease Drug Type C1, Niemann-Pick Disease Drug Type C2), by Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, And Africa) Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Dec 2022
Code : CMI4275
Pages :362
Formats :
Excel and PDF
Industry : Pharmaceutical

Regional Analysis

Global Niemann-Pick Disease Drug Type C Treatment Market – Regional Analysis

On the basis of region, the global niemann-pick disease drug type C treatment market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America is expected to be the most lucrative region in the global niemann-pick disease Drug Type C, owing to increasing number of product approvals from regulatory authorities. For instance, on September 16, 2020, Orphazyme A/S, a biopharmaceutical company, received the U.S. Food and Drug Administration (FDA) approval, with priority review for New Drug Application (NDA), for arimoclomol for the treatment of Niemann Pick disease type C (NPC).

Europe is expected to witness significant growth in the forecast period, owing to increasing research and development activities for Niemann-Pick Disease Type C treatment. For instance, on September 30, 2020, IntraBio Inc., a private pharmaceutical company, announced positive results for the Phase II clinical trial, which is carried out for testing the safety and efficacy of drug candidate, IB1001, for the treatment of NPC. The clinical trial showed a decrease in the severity of ataxia, a symptom of NPC and the trial also passed the endpoint for Clinical Impression of Change in Severity (CI-CS).